Browsing Tag
idiopathic hypersomnia
3 posts
Lilly bets $7.8bn on orexin science with Centessa acquisition as neuroscience race intensifies
Eli Lilly agrees to acquire Centessa Pharmaceuticals for $6.3B, gaining orexin sleep drug cleminorexton. Read the full strategic analysis.
Alkermes raises Avadel bid to $2.37bn with enhanced CVR terms tied to LUMRYZ FDA milestone
Alkermes raises Avadel bid to $2.37B with improved CVR linked to FDA approval for LUMRYZ in idiopathic hypersomnia. Read the full transaction breakdown.
Harmony Biosciences faces FDA setback for pitolisant in idiopathic hypersomnia
Harmony Biosciences Holdings, Inc. has encountered a regulatory hurdle in its efforts to expand the use of pitolisant…